235 related articles for article (PubMed ID: 16720366)
21. Incorporation of the catalytic domain of a hammerhead ribozyme into antisense RNA enhances its inhibitory effect on the replication of human immunodeficiency virus type 1.
Homann M; Tzortzakaki S; Rittner K; Sczakiel G; Tabler M
Nucleic Acids Res; 1993 Jun; 21(12):2809-14. PubMed ID: 8332489
[TBL] [Abstract][Full Text] [Related]
22. Resistance to human immunodeficiency virus type 1 (HIV-1) infection in human CD4+ lymphocyte-derived cell lines conferred by using retroviral vectors expressing an HIV-1 RNA-specific ribozyme.
Weerasinghe M; Liem SE; Asad S; Read SE; Joshi S
J Virol; 1991 Oct; 65(10):5531-4. PubMed ID: 1895402
[TBL] [Abstract][Full Text] [Related]
23. Activity and cleavage site specificity of an anti-HIV-1 hairpin ribozyme in human T cells.
Yamada O; Kraus G; Leavitt MC; Yu M; Wong-Staal F
Virology; 1994 Nov; 205(1):121-6. PubMed ID: 7975207
[TBL] [Abstract][Full Text] [Related]
24. Multivalent anti-CCR ribozymes for stem cell-based HIV type 1 gene therapy.
Bai J; Rossi J; Akkina R
AIDS Res Hum Retroviruses; 2001 Mar; 17(5):385-99. PubMed ID: 11282007
[TBL] [Abstract][Full Text] [Related]
25. A multifunctional expression vector for an anti-HIV-1 ribozyme that produces a 5'- and 3'-trimmed trans-acting ribozyme, targeted against HIV-1 RNA, and cis-acting ribozymes that are designed to bind to and thereby sequester trans-activator proteins such as Tat and Rev.
Yuyama N; Ohkawa J; Koguma T; Shirai M; Taira K
Nucleic Acids Res; 1994 Nov; 22(23):5060-7. PubMed ID: 7800500
[TBL] [Abstract][Full Text] [Related]
26. Co-packaging of sense and antisense RNAs: a novel strategy for blocking HIV-1 replication.
Ding SF; Noronha J; Joshi S
Nucleic Acids Res; 1998 Jul; 26(13):3270-8. PubMed ID: 9628929
[TBL] [Abstract][Full Text] [Related]
27. Retrovirally expressed anti-HIV ribozymes confer a selective survival advantage on CD4+ T cells in vitro.
Klebba C; Ottmann OG; Scherr M; Pape M; Engels JW; Grez M; Hoelzer D; Klein SA
Gene Ther; 2000 Mar; 7(5):408-16. PubMed ID: 10694823
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic applications of catalytic antisense RNAs (ribozymes).
Rossi JJ
Ciba Found Symp; 1997; 209():195-204; discussion 204-6. PubMed ID: 9383577
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of HIV-1 multiplication in a human CD4+ lymphocytic cell line expressing antisense and sense RNA molecules containing HIV-1 packaging signal and Rev response element(s).
Cohli H; Fan B; Joshi RL; Ramezani A; Li X; Joshi S
Antisense Res Dev; 1994; 4(1):19-26. PubMed ID: 7914762
[TBL] [Abstract][Full Text] [Related]
30. Enhanced inhibition of human immunodeficiency virus type 1 replication by novel lentiviral vectors expressing human immunodeficiency virus type 1 envelope antisense RNA.
Mautino MR; Morgan RA
Hum Gene Ther; 2002 Jun; 13(9):1027-37. PubMed ID: 12067436
[TBL] [Abstract][Full Text] [Related]
31. Length variation of helix III in a hammerhead ribozyme and its influence on cleavage activity.
Hammann C; Martinez E; Moosbauer J; Hormes R; Tabler M
Antisense Nucleic Acid Drug Dev; 1999 Feb; 9(1):25-31. PubMed ID: 10192286
[TBL] [Abstract][Full Text] [Related]
32. Intracellular expression of RNA transcripts complementary to the human immunodeficiency virus type 1 gag gene inhibits viral replication in human CD4+ lymphocytes.
Veres G; Escaich S; Baker J; Barske C; Kalfoglou C; Ilves H; Kaneshima H; Böhnlein E
J Virol; 1996 Dec; 70(12):8792-800. PubMed ID: 8971008
[TBL] [Abstract][Full Text] [Related]
33. Preclinical characterization of an anti-tat ribozyme for therapeutic application.
Wang L; Witherington C; King A; Gerlach WL; Carr A; Penny R; Cooper D; Symonds G; Sun LQ
Hum Gene Ther; 1998 Jun; 9(9):1283-91. PubMed ID: 9650613
[TBL] [Abstract][Full Text] [Related]
34. Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication--potential effectiveness against most presently sequenced HIV-1 isolates.
Chen CJ; Banerjea AC; Harmison GG; Haglund K; Schubert M
Nucleic Acids Res; 1992 Sep; 20(17):4581-9. PubMed ID: 1408760
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by HIV-1-based lentivirus vectors expressing transdominant Rev.
Mautino MR; Keiser N; Morgan RA
J Virol; 2001 Apr; 75(8):3590-9. PubMed ID: 11264348
[TBL] [Abstract][Full Text] [Related]
36. Recombinant AAV-2 harboring gfp-antisense/ribozyme fusion sequences monitor transduction, gene expression, and show anti-HIV-1 efficacy.
Hörster A; Teichmann B; Hormes R; Grimm D; Kleinschmidt J; Sczakiel G
Gene Ther; 1999 Jul; 6(7):1231-8. PubMed ID: 10455431
[TBL] [Abstract][Full Text] [Related]
37. The antisense sequence of the HIV-1 TAR stem-loop structure covalently linked to the hairpin ribozyme enhances its catalytic activity against two artificial substrates.
Pérez-Ruiz M; Sievers D; García-López PA; Berzal-Herranz A
Antisense Nucleic Acid Drug Dev; 1999 Feb; 9(1):33-42. PubMed ID: 10192287
[TBL] [Abstract][Full Text] [Related]
38. Cross-clade inhibition of HIV-1 replication and cytopathology by using RNase P-associated external guide sequences.
Kraus G; Geffin R; Spruill G; Young AK; Seivright R; Cardona D; Burzawa J; Hnatyszyn HJ
Proc Natl Acad Sci U S A; 2002 Mar; 99(6):3406-11. PubMed ID: 11904403
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of HIV-1 replication by an anti-tat hammerhead ribozyme.
Jackson WH; Moscoso H; Nechtman JF; Galileo DS; Garver FA; Lanclos KD
Biochem Biophys Res Commun; 1998 Apr; 245(1):81-4. PubMed ID: 9535787
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of HIV-1 replication by novel lentiviral vectors expressing transdominant Rev and HIV-1 env antisense.
Mautino MR; Morgan RA
Gene Ther; 2002 Apr; 9(7):421-31. PubMed ID: 11938457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
